Ventricular Tachyarrhythmias Clinical Trial
— Chronic IIOfficial title:
Initial Chronic Human Validation Study: Subcutaneous Implantable Cardioverter Defibrillator (S-ICD) System
NCT number | NCT00853645 |
Other study ID # | DN-11398 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | July 2008 |
Est. completion date | September 2008 |
Verified date | July 2021 |
Source | Boston Scientific Corporation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Primary objective is to evaluate the safety and performance of the implanted Subcutaneous implantable cardioverter defibrillator (S-ICD) system. A maximum of 10 subjects were to be enrolled and followed for one month to collect data on the safety, efficacy, and performance of the implanted S-ICD system. Additionally, patient comfort will be assessed as will cosmetic outcome.
Status | Completed |
Enrollment | 6 |
Est. completion date | September 2008 |
Est. primary completion date | September 2008 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - replacement of an existing transvenous implantable cardioverter defibrillator (ICD) system - American College of Cardiology/American Heart Association/Heart Rhythm Society (ACC/AHA/HRS) Class I or II indications for ICD implantation - Age >= 18 years - Appropriate pre-operative Electrocardiogram (ECG) as measured with a specially developed template Exclusion Criteria: - Subjects unable or unwilling to provide informed consent - Any condition which precludes the subject's ability to comply with the study requirements - Females who are pregnant or lactating and pre-menopausal women who are unwilling to use adequate birth control for the duration of the study - Participation in another investigational device trial at any time during the conduct of the S-ICD system trial without written consent from the sponsor. - Patients with a serious medical condition and life expectancy of less than one year. - Patients with documented spontaneous and frequently recurring ventricular tachyarrhythmias (VT) that is reliably terminated with anti-tachycardia pacing - Patients with existing epicardial patches or subcutaneous electrodes in the left thoracic quadrant - Patients with chronic renal failure, i.e. with a creatinine level of >2.5 mg/dl unless prescribed drug therapy known to increase creatinine levels in which case the value should be <= 3mg/dl |
Country | Name | City | State |
---|---|---|---|
New Zealand | Auckland City Hospital | Auckland | |
New Zealand | Christchurch Hospital | Christchurch |
Lead Sponsor | Collaborator |
---|---|
Boston Scientific Corporation |
New Zealand,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With a Successful Induced Ventricular Fibrillation Conversion | Sustained ventricular fibrillation induced by the investigator is successfully converted. A successful conversion was defined as two consecutive successful shocks out of four attempts with either standard polarity or with reverse polarity. | 30 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT05084391 -
Phase I/II Randomized Study of Stereotactic Ablative Radiotherapy (SABR) Versus Standard of Care for Refractory Structural Cardiac Arrhythmias (SABR-HEART)
|
Phase 1/Phase 2 | |
Completed |
NCT01492764 -
Ablation of Ventricular Fibrillation by Accurate Targeting of Arrhythmogenic Regions (AVATAR)
|
||
Completed |
NCT01906775 -
Sub-threshold Pacing to Prevent Pacemaker-induced Ventricular Tachycardia
|
N/A |